Sarepta Therapeutics’ Duchenne therapy faces ‘arduous’ path back to market, senior FDA official says - statnews.com

Sarepta Therapeutics, the maker of a gene therapy for Duchenne muscular dystrophy that is being temporarily shelved because of safety concerns, faces an arduous and treacherous path to try to get it …